So, basically, there are two case studies here:
- One with Bowenoid Actinic Keratosis and
- Second with Bowen’s Disease.
Both of these cases were treated with Ingenol mebutate (IM), a topical pharmacotherapy approved in Switzerland in 2012 for treating non-hyperkeratotic and non-hypertrophic actinic keratosis (AK).
The first case of bowenoid AK was treated with 150 μg IM for 3 continuous days with an almost complete decrease in the lesion. The second case of Bowen’s disease was treated with 500 μg IM for 2 continuous days leading to a complete decrease in the lesion.
The first case was a 78-year-old female patient who was confirmed with bowenoid AK at the lateral commissure of her lower left eyelid. Topical modalities including photodynamic therapy (PDT) and imiquimod (IQ) had been performed with varying success. The doctors decided to apply 150 μg IM for 3 consecutive days as an off-label treatment for this bowenoid AK. A local skin reaction around the left eye with erosion and erythema was seen, with the disappearance of pigmentation and remaining erythema without scaling at 2 weeks of follow-up. An almost complete clinical regression of the pigmentation was seen at the 6-month follow-up.
The second case was a 73-year-old male patient who has a history of dermatitis and presented with a new skin lesion on the left dorsum of the hand. The doctors started an off-label treatment with 500 μg IM for 2 consecutive days, leading to a crust formation, which resolved after 1 week with complete clinical remission at 6 weeks follow-up.
These 2 cases show that Ingenol mebutate (IM) can be effective in the treatment of Bowenoid Actinic Keratosis and Bowen’s disease.
Make sure to consult your doctor to get the treatment required for Bowenoid Actinic Keratosis and Bowen’s disease.